DBV Technologies Facing Financial Uncertainties in Q3 2024

DBV Technologies has released its financial results for the third quarter of 2024. The company reported a significant cash decrease, ending the quarter with $46.4 million, down from $141.4 million at the end of 2023. This drop is attributed mainly to expenses related to clinical trials and regulatory activities.

The operating income for the nine months ended September 30, 2024, was $3.6 million, down from $6.9 million a year earlier. This decline stems from the termination of an agreement with NESTEC and reduced Research Tax Credit benefits.

DBV incurred a net loss of $90.9 million for the same period, marking an increase from a $61.5 million loss the previous year. The company plans to raise additional capital to continue operations into Q1 2025 but faces uncertainty due to potential economic challenges.